Medical testing companies, Natera Inc. and Eurofins Viracor LLC, recently urged the U.S. Supreme Court to refrain from reviewing the invalidation of Stanford University and CareDx patents for their innovatory blood test. The blood test, crucial for detecting organ rejection, had its patents invalidated as they were deemed to cover only natural phenomena. Law360 reported this occurrence.
The latest development showcases the ongoing patent eligibility dilemma present within the realm of medical diagnostics. It begs the question if unique approaches, even if derived from natural phenomena, deserve patent protection or if such protection should be restricted strictly to wholly man-made pharmaceuticals and medical devices.
This pressing issue demands the attention of all legal practitioners involved in the health sciences vertical, debating and navigating the delicate balance between promoting innovation and preserving a fair commercial field for new players to operate.
The case also emphasizes a broader issue of patent eligibility within the United States. Legal professionals tasked with drafting and litigating patents must remain vigilant for such potential developments, ensuring that they navigate the changing landscape in a way that best serves their clients and the innovative breakthroughs they shepherd into the marketplace.
As the matter develops, the legal community and the health sector await the Supreme Court’s response, which would likely have significant implications for the future of patent law and medical diagnostic development.